| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Endocrinology, Vol 6, 2136-2142, Copyright © 1992 by Endocrine Society
ARTICLES |
Y Yamada, T Reisine, SF Law, Y Ihara, A Kubota, S Kagimoto, M Seino, Y Seino, GI Bell and S Seino
Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.
We previously reported the cloning of two distinct somatostatin receptor (SSTR) subtypes, SSTR1 and SSTR2. Although both SSTR1 and SSTR2 bound somatostatin specifically and with high affinity, neither was coupled to adenylyl cyclase, a major cellular effector of somatostatin's actions. Here we report the cloning and functional characterization of a third member of the SSTR family. Human SSTR3 is a protein of 418 amino acids and has 45% and 46% identity with human SSTR1 and SSTR2, respectively. RNA blotting studies showed that SSTR3 mRNA could be readily detected in brain and pancreatic islets. The pharmacological properties of human SSTR3 were characterized by transiently expressing the human SSTR3 gene in COS-1 cells. Membranes from cells expressing human SSTR3 bound the somatostatin agonist [125I]CGP 23996 specifically and with high affinity, with a rank order of potency of somatostatin-28 = CGP 23996 > somatostatin-14 > SMS-201- 995. Studies using cells transiently coexpressing the human dopamine D1 receptor and human SSTR3 showed that somatostatin was able to inhibit dopamine-stimulated cAMP formation in a dose-dependent manner, indicating that SSTR3 was functionally coupled to adenylyl cyclase. These results indicate that the diverse biological effects of somatostatin are mediated by a family of receptor with distinct, but overlapping, tissue distributions, unique pharmacological properties, and potentially different functions.
This article has been cited by other articles:
 |
|
 |
|
  A. Ben-Shlomo, C. Zhou, O. Pichurin, V. Chesnokova, N.-A. Liu, M. D. Culler, and S. Melmed Constitutive Somatostatin Receptor Activity Determines Tonic Pituitary Cell Response Mol. Endocrinol., March 1, 2009; 23(3): 337 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Seino and T. Shibasaki PKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis Physiol Rev, October 1, 2005; 85(4): 1303 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Ludvigsen, M Stridsberg, E T Janson, and S Sandler Expression of somatostatin receptor subtypes 1-5 in pancreatic islets of normoglycaemic and diabetic NOD mice Eur. J. Endocrinol., September 1, 2005; 153(3): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ludvigsen, R. Olsson, M. Stridsberg, E. T. Janson, and S. Sandler Expression and Distribution of Somatostatin Receptor Subtypes in the Pancreatic Islets of Mice and Rats J. Histochem. Cytochem., March 1, 2004; 52(3): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Burggasser, I. Hurtl, W. Hauff, J. Lukas, M. Greifeneder, B. Heydari, A. Thaler, A. Wedrich, and I. Virgolini Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves' Disease J. Nucl. Med., October 1, 2003; 44(10): 1547 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Simonneaux and C. Ribelayga Generation of the Melatonin Endocrine Message in Mammals: A Review of the Complex Regulation of Melatonin Synthesis by Norepinephrine, Peptides, and Other Pineal Transmitters Pharmacol. Rev., June 1, 2003; 55(2): 325 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly Endocr. Rev., October 1, 2002; 23(5): 623 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parkinson, W. M. Drake, M. E. Roberts, K. Meeran, G. M. Besser, and P. J. Trainer A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1797 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kundra, F. Mannting, A. G. Jones, and A. I. Kassis Noninvasive Monitoring of Somatostatin Receptor Type 2 Chimeric Gene Transfer J. Nucl. Med., March 1, 2002; 43(3): 406 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kulaksiz, R Eissele, D Rossler, S Schulz, V Hollt, Y Cetin, and R Arnold Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut, January 1, 2002; 50(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fueger, G. Hamilton, M. Raderer, T. Pangerl, T. Traub, P. Angelberger, G. Baumgartner, R. Dudczak, and I. Virgolini Effects of Chemotherapeutic Agents on Expression of Somatostatin Receptors in Pancreatic Tumor Cells J. Nucl. Med., December 1, 2001; 42(12): 1856 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Traub, V. Petkov, S. Ofluoglu, T. Pangerl, M. Raderer, B. J. Fueger, W. Schima, A. Kurtaran, R. Dudczak, and I. Virgolini 111In-DOTA-Lanreotide Scintigraphy in Patients with Tumors of the Lung J. Nucl. Med., September 1, 2001; 42(9): 1309 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Danila, J. N. S. Haidar, X. Zhang, L. Katznelson, M. D. Culler, and A. Klibanski Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2976 - 2981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Bohuslavizki Somatostatin Receptor Imaging: Current Status and Future Perspectives J. Nucl. Med., July 1, 2001; 42(7): 1057 - 1058. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Sheridan, J. D. Kittilson, and B. J. Slagter Structure-Function Relationships of the Signaling System for the Somatostatin Peptide Hormone Family Integr. Comp. Biol., April 1, 2000; 40(2): 269 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Strowski, R. M. Parmar, A. D. Blake, and J. M. Schaeffer Somatostatin Inhibits Insulin and Glucagon Secretion via Two Receptor Subtypes: An in Vitro Study of Pancreatic Islets from Somatostatin Receptor 2 Knockout Mice Endocrinology, January 1, 2000; 141(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Smith-Jones, C. Bischof, M. Leimer, D. Gludovacz, P. Angelberger, T. Pangerl, M. Peck-Radosavljevic, G. Hamilton, K. Kaserer, A. Kofler, et al. DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy Endocrinology, November 1, 1999; 140(11): 5136 - 5148. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Helboe and M. Moller Immunohistochemical Localization of Somatostatin Receptor Subtypes sst1 and sst2 in the Rat Retina Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2376 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Mitra, E. Mezey, B. Hunyady, L. Chamberlain, E. Hayes, F. Foor, Y. Wang, A. Schonbrunn, and J. M. Schaeffer Colocalization of Somatostatin Receptor sst5 and Insulin in Rat Pancreatic {beta}-Cells Endocrinology, August 1, 1999; 140(8): 3790 - 3796. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Georgii-Hemming, T. Stromberg, E. T. Janson, M. Stridsberg, H. J. Wiklund, and K. Nilsson The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6 (IL-6)-Dependent and IL-6-Independent Human Multiple Myeloma Cell Lines Blood, March 1, 1999; 93(5): 1724 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Medina, J. A. Velasco, and P. Santisteban Somatostatin Is Expressed in FRTL-5 Thyroid Cells and Prevents Thyrotropin-Mediated Down-Regulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Endocrinology, January 1, 1999; 140(1): 87 - 95. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Skinner, R. Nass, B. Lopes, E. R. Laws, and M. O. Thorner Growth Hormone Secretagogue Receptor Expression in Human Pituitary Tumors J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4314 - 4320. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Helboe, C. E. Stidsen, and M. Moller Immunohistochemical and Cytochemical Localization of the Somatostatin Receptor Subtype sst1 in the Somatostatinergic Parvocellular Neuronal System of the Rat Hypothalamus J. Neurosci., July 1, 1998; 18(13): 4938 - 4945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-J. Zhu, K. Krempels, C. W. Bardin, A.-M. O'Carroll, and E. Mezey The Localization of Messenger Ribonucleic Acids for Somatostatin Receptors 1, 2, and 3 in Rat Testis Endocrinology, January 1, 1998; 139(1): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Caron, L. Buscail, A. Beckers, J.-P. Esteve, A. Igout, G. Hennen, and C. Susini Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3771 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Aurang, J. Wang, and K. C. K. Lloyd Somatostatin Inhibition of Acid and Histamine Release by Activation of Somatostatin Receptor Subtype 2 Receptors in Rats J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 245 - 252. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Liapakis, D. Fitzpatrick, C. Hoeger, J. Rivier, R. Vandlen, and T. Reisine Identification of Ligand Binding Determinants in the Somatostatin Receptor Subtypes 1and 2 J. Biol. Chem., August 23, 1996; 271(34): 20331 - 20339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland Octreotide N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
